Q2 2025 Pharma Services Update
Pharmaceutical Commercialization Subsector Highlight:
M&A activity within the pharmaceutical commercialization sector remained strong in Q2-25 with a total of 11 closed transactions. Despite a marginal decrease in QoQ deal volume and minimal platform creation activity by private equity sponsors, Provident anticipates strong future M&A volume driven by the near-term recapitalizations of several scaled, private equity-backed strategic operators.
PharmaCord’s merger with Mercalis emphasizes a broader trend of consolidation in the outsourced pharma services sector. Strategic players are increasingly looking to leverage technologies and AI to enhance service offerings. Datavant’s acquisition of Aetion, a leading real-world evidence (RWE) solutions provider, similarly demonstrates a growing demand for data-driven insights to support commercialization services.
To print and download the full Pharma Services Update report, please click below…
